0000899243-22-030336.txt : 20220902
0000899243-22-030336.hdr.sgml : 20220902
20220902193518
ACCESSION NUMBER: 0000899243-22-030336
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220831
FILED AS OF DATE: 20220902
DATE AS OF CHANGE: 20220902
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Huang James
CENTRAL INDEX KEY: 0001573160
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-20713
FILM NUMBER: 221226565
MAIL ADDRESS:
STREET 1: 9620 MEDICAL CENTER DRIVE
STREET 2: SUITE 300
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CASI Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0000895051
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 581959440
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9620 MEDICAL CENTER DR
STREET 2: STE 300
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-864-2600
MAIL ADDRESS:
STREET 1: 9620 MEDICAL CENTER DR
STREET 2: STE 300
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: ENTREMED INC
DATE OF NAME CHANGE: 19960415
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-08-31
0
0000895051
CASI Pharmaceuticals, Inc.
CASI
0001573160
Huang James
C/O CASI PHARMACEUTICALS, INC.
9620 MEDICAL CENTER DR. SUITE 300
ROCKVILLE
MD
20850
1
0
0
0
Common Stock
2022-08-31
4
P
0
24975
3.745
A
303723
I
See Footnote
Common Stock
2022-09-01
4
P
0
11821
3.7229
A
315544
I
See Footnote
Common Stock
2022-09-02
4
P
0
400
3.7413
A
315944
I
See Footnote
Common Stock
191
D
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.69 to $3.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.
The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.71 to $3.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
/s/ James Huang
2022-09-02